EO4010
Third-line Colorectal Cancer
Phase 2Active
Key Facts
About Enterome
Enterome is a pioneering French biotech translating microbiome science into innovative cancer immunotherapies. Its proprietary Mimicry platform screens a vast database of gut microbiome proteins to discover OncoMimics™, off-the-shelf peptide therapies designed to overcome immune tolerance. The company has advanced three Phase 2 candidates targeting glioblastoma, lymphomas, adrenal tumors, and colorectal cancer, demonstrating promising early efficacy and safety. With strong leadership and significant capital raised, Enterome is positioned as a key player in the next wave of immuno-oncology.
View full company profile